DexCom drops after Abbott's diabetes sensors cleared for insulin delivery system integration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), 'a preferential tiering for Libre could position it better for share gains in the larger T2 market'
March 6, 2023 10:19 AM ESTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $114.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Market opportunity / implications: The T1 market is smalland we would expect ABT to get some incremental share in the T1 market going... More
Wolfe on DexCom (DXCM) as Shares Slide over 5 pct: 'we think risk of an exodus of current DXCM users for Libre is extremely low'
March 6, 2023 10:16 AM ESTWolfe on DexCom (NASDAQ: DXCM) as Shares Slide over 5 pct: 'we think risk of an exodus of current DXCM users for Libre is extremely low'.
Analyst Mike Polark comments "This morning, ABT announced that the FDA cleared Libre 2 and 3 for automated insulin delivery (AID): Modified versions of the sensor were cleared. What was changed? We asked the company. Reply? Modest adjustment to how the sensor... More
Abbott (ABT) Announces FDA Clearance of FreeStyle Libre 2 and FreeStyle Libre 3 Sensors
March 6, 2023 7:06 AM ESTAbbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems.
"Our goal is to make diabetes care as easy as possible," said Jared Watkin, senior vice president for Abbott's diabetes care business. "The FreeStyle Libre portfolio is already the most prescribed CGM in the United States³ and, with the integration of automated insulin... More
Krystal Biotech (KRYS) Appoints Catherine Mazzacco to its Board
March 6, 2023 7:05 AM ESTKrystal Biotech, Inc. (the Company) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors.
I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystals evolution, said Krish S.... More
